Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Post by Carlos66on Jan 19, 2017 12:16pm
215 Views
Post# 25728612

FYI...mergers in animal health sector

FYI...mergers in animal health sectorWith the recent sign-off from the U.S. Federal Trade Commission, privately held Boehringer Ingelheim is set absorb Sanofi's (SNY -0.1%) animal health unit Merial, making it the number two player in the veterinary medicine field behind Zoetis (ZTS +0.2%). With Merck (MRK) and Eli Lilly (LLY +0.4%), the four firms control the bulk of the industry.

According to Handelsblatt Global's Siegfried Hofman, the concentration of market heft makes further consolidation unlikely, although Bayer (OTCPK:BAYRY +1.2%) is rumored to be amenable to divesting its animal health business. Merck would be a likely acquirer. Judging by other transactions, the deal would probably be valued between €6B - 8B.

I wonder if less players in the field means less opportunity to sell VIV's products.

carlos
Bullboard Posts